ATX-624
Asset
Allosterically inhibits SARM1 by gluing two protein domains together, stabilizing its inactive structure.
- Stage
- Preclinical
- Modality
- Small molecule
- Target
- SARM1
- 3
- Indications
- 0
- Trials
- 1
- Developer
Indications
3ADOA
Preclinical, firstatomtx.com, 10 Oct 2026
Amyotrophic lateral sclerosis
Preclinical, firstatomtx.com, 10 Oct 2026
Chemotherapy-induced neuropathy
Preclinical, firstatomtx.com, 10 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.